| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S5882 R14694 |
Ban (Controls unexposed, disease free), 2014 | Chromosomal malformations | 1st trimester | retrospective cohort (claims database) | unexposed, disease free | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.38 [0.09;1.15] | -/3,189 551/325,294 | - | 3,189 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6016 R15544 |
Jimenez-Solem (Controls unexposed, NOS), 2012 | Chromosomal abnormalities | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.97 [0.14;6.92] | 1/928 -/843,797 | - | 928 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7194 R20428 |
Colvin, 2011 | Chromosome defects | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) | 0.75 [0.05;12.06] C | 0/291 216/94,561 | 216 | 291 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 0.53 [0.20;1.43] | 216 | 4,408 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, disease free; 2: Controls unexposed, NOS;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded